NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ACCPL · data 2026-10-31
Accretion Pharmaceuticals Ltd.
In plain words
Price: 13.6% below its 52-week high of ₹220.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹90 cr |
| Net profit (last 12 months) | ₹10 cr |
| Sales growth, 3 years (yearly) | 45.0% |
| Profit growth, 3 years (yearly) | 353.1% |
At a glance
P/E 21.9, P/B 3.9, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 27.6%, ROCE 38.3%, operating margin 15.3%: how much profit it earns on the money it uses.
Debt/equity 0.23, Profit growth 353.1% and sales growth 45.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (27.6%).
- Profit grew 353.1% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Accretion Pharmaceuticals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.23.
What is Accretion Pharmaceuticals Ltd.'s P/E ratio?
About 21.9, based on the last 12 months' earnings and a price of ₹190.05 (data 2026-10-31).
What is the 52-week high and low of Accretion Pharmaceuticals Ltd.?
The 52-week high is ₹220 and the 52-week low is ₹54.6.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Accretion Pharmaceuticals Ltd. | ₹190.05 | ₹211 cr | 21.9 | 3.9 | 27.6% | 38.3% | 0.23 | +234.9% |
| Aarey Drugs & Pharmaceuticals Ltd. | ₹106.26 | ₹298 cr | 72.4 | — | 2.7% | 6% | 0.33 | +15.4% |
| Ambalal Sarabhai Enterprises Limited | ₹34.99 | ₹268 cr | 19.8 | — | 11.9% | 9.4% | 0.36 | +8.3% |
| Nectar Lifesciences Ltd. | ₹10.2 | ₹200 cr | — | — | -7.5% | -0.9% | 0 | -38.3% |
| Brooks Laboratories Limited | ₹60.56 | ₹179 cr | 13.5 | — | 22.3% | 4.8% | 0.07 | -43.3% |
| Medico Remedies Ltd. | ₹18.61 | ₹155 cr | 11.2 | — | 19% | 20.4% | 0.26 | -61.3% |
Compare ACCPL with AAREYDRUGS in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ACCPL in NSE Scanner →